Calyx & Invicro to Merge for Medical Imaging Solutions

Both Calyx and Invicro provide complementary services to leading pharmaceutical and biotechnology companies globally.

Calyx, a technology-enabled service provider for medical imaging has merged with Invicro, a next-generation quantitative imaging biomarker company. This collaboration aims to establish a new global leader in medical imaging solutions and development services for the clinical research community.

The transaction involves Calyx acquiring 100% of Invicro from its current owner, REALM IDx, Inc, and is subject to regulatory filings and customary closing conditions. The completion of the transaction is anticipated in the second quarter of 2024.

Commenting on the transaction, David Herron, CEO, Calyx, said, "Calyx and Invicro are uniquely complementary businesses in terms of their scientific talent, service offerings, and international presence. This exciting union will create a truly differentiated industry leader and provides a clear response to growing customer requirements for broader support. Our leadership will be evident in terms of the Group's global reach across the US, Europe and Asia, and, critically, our extensive scientific knowledge, capabilities and experience.”

He continued to note that this combined expertise and broader specialist support creates a compelling customer proposition for the greater biopharma industry, ranging from large pharma companies to specialty biotech firms.

“This spans the complete R&D lifecycle from discovery through research and development to post-marketing, across a number of areas including imaging biomarkers, core lab services, analytics and software," he added.

Complementary Offerings for Pharma & Biotech Companies

Both Calyx and Invicro provide complementary services to leading pharmaceutical and biotechnology companies globally. The combined Group resulting from this collaboration will employ approximately 2,000 highly skilled employees across ten sites in the US, Europe, and Asia.

This expanded footprint aims to position the Group to offer a comprehensive suite of solutions to clients worldwide. The consolidation supports nearly 12,000 clinical and research trials to date across all clinical phases, with a focus on oncology and the central nervous system (CNS).

Additionally, the Group is expected to work on enhancing its R&D capabilities to provide scientific and service support in preclinical and exploratory work.

Regarding the merger, Edward Hogan, COO, Invicro, said, "We are very excited about the impending combination of our two companies. We see a huge opportunity in uniting highly skilled teams of scientists and researchers to enable us to work more closely with our partners.”

According to Hogan, the partnership aims to jointly work towards the development of new life-saving therapies to provide better outcomes for patients in therapeutic areas, including oncology and the central nervous system (CNS).

This also includes unique specialist radioligand therapy capabilities to meet the growing demand for enhanced imaging and new treatments in fast-growing specialties such as radiotherapy, gastroenterology, inflammation, fibrosis and mitochondrial imaging.

Following the completion of the transaction, the process of combining and integrating Calyx and Invicro will commence. During this period, the companies state that the primary focus will be on ensuring that customers receive the same high-quality service and support they have come to expect from both entities. The integration will involve harmonizing operations to provide a seamless experience for clients.

Calyx is a leading global technology-enabled service provider for medical imaging and IRT/RTSM (Interactive Response Technology/Randomized Trial Supply Management) for drug developers and the global clinical research community.

Headquartered in the US, Invicro is a next-generation quantitative imaging biomarker company focused on accelerating the discovery and development of life-changing medicines.

In another development in the medical imaging space, Stratasys, a polymer 3D printing and additive manufacturing solutions specialist, teamed up with Siemens Healthineers to embark on a research project aimed at revolutionizing medical imaging phantoms for computed tomography (CT).

The collaborative effort seeks to develop innovative solutions by leveraging Stratasys' PolyJet technology, RadioMatrix technology, and Siemens Healthineers' advanced algorithms to enhance the accuracy and realism of CT phantoms.